He received advanced training in pathology at the Hammersmith Hospital in London, United Kingdom, where he also conducted research in toxicology.
He has also served on various committees, including those of the World Health Organization, where he provided expert guidance on the biological impacts of toxic substances.
Sibte Hasan Zaidi was born in Barabanki, India, and spent his early years in the village town of Jarwal under the care of his maternal uncle after the death of his mother, Zakia Begum.
After completing his clinical training and briefly serving as an academic in Pathology at King George’s Medical College, Zaidi moved to London.
Zaidi and co-workers "produced the nearest approach to massive fibrosis by injecting into sensitized animals dust plus tubercle bacilli.
"[2] In 1955, Zaidi traveled back to India to be named Head of the Division of Experimental Medicine and Deputy Director at the Central Drug Research Institute (CDRI) in Lucknow, India, where his research focused on mechanisms that underlie peptic ulcer, atherosclerosis, vasospasm, and eosinophilia.
Through pharmacologic and animal studies, Zaidi and his colleagues demonstrated the requirement of a mucus barrier in the prevention of peptic ulcer disease.
[4] He also examined the mechanisms of hypercoagulability and thrombosis and developed rodent models of atherosclerotic heart disease and myocardial infarction.
[9] His editorial "Bhopal and After",[10] published in the American Journal of Industrial Medicine and later quoted in several articles,[11] highlighted gaps in 1980s policy that could lead to spillage of chemicals.
He was awarded the Sir Ardeshirlal Dalal Gold Medal for his contributions to occupational health (1975), and the Padam Shree (1977) by the Government of India.